These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Authors' response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection. Harder T; Koch J; Vygen-Bonnet S; Külper-Schiek W; Pilic A; Reda S; Scholz S; Wichmann O Euro Surveill; 2021 Sep; 26(35):. PubMed ID: 34477051 [No Abstract] [Full Text] [Related]
4. Authors' Reply to Sprengholz and Betsch: "Willingness to Pay for a COVID-19 Vaccine". García LY; Cerda AA Appl Health Econ Health Policy; 2021 Jul; 19(4):623-624. PubMed ID: 33973149 [No Abstract] [Full Text] [Related]
5. COVID-19 Vaccine in Children: Where Do We Stand?: Authors' Reply. Kasi SG; Shah A Indian Pediatr; 2021 Feb; 58(2):195. PubMed ID: 33632967 [No Abstract] [Full Text] [Related]
6. SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply. Alexander JL; Kennedy NA; Lees CW; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):523-524. PubMed ID: 34119033 [No Abstract] [Full Text] [Related]
7. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply. Voysey M; Pollard AJ Lancet; 2020 Nov; 396(10261):1486-1487. PubMed ID: 33160565 [No Abstract] [Full Text] [Related]
8. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply. Logunov DY; Dolzhikova IV; Shcheblyakov DV Lancet; 2021 May; 397(10288):1883-1884. PubMed ID: 33991474 [No Abstract] [Full Text] [Related]
9. Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply. Logunov DY; Dolzhikova IV; Tukhvatullin AI; Shcheblyakov DV Lancet; 2020 Oct; 396(10256):e54-e55. PubMed ID: 32971043 [No Abstract] [Full Text] [Related]
14. Humoral responses to coronavirus disease 2019 vaccines in people with HIV: authors' reply. Wong NS; Wong BCK; Chan JMC; Wong KH; Tsang OTY; Lee SS; Chan DPC AIDS; 2022 Oct; 36(12):1747-1748. PubMed ID: 36052544 [No Abstract] [Full Text] [Related]
16. [Reply to "Defining priorities, the case of of COVID-19 vaccine"]. Indolfi C; Barillà F; Basso C; Ciccone MM; Curcio A; Mancone M; Mercuro G; Muscoli S; Nodari S; Pedrinelli R; Romeo F; Sinagra G; Filardi PP G Ital Cardiol (Rome); 2021 Jun; 22(6):510-511. PubMed ID: 34037598 [No Abstract] [Full Text] [Related]
17. Reply to Rabb et al.: Why promoting COVID-19 vaccines with community immunity is not a good strategy (yet). Korn L; Böhm R; Betsch C Proc Natl Acad Sci U S A; 2021 Apr; 118(14):. PubMed ID: 33762431 [No Abstract] [Full Text] [Related]
18. BNT162b2 Covid-19 Vaccine in Adolescents. Reply. Frenck RW; Dormitzer PR; Gurtman A N Engl J Med; 2021 Sep; 385(14):1343. PubMed ID: 34525284 [No Abstract] [Full Text] [Related]
19. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply. Absalon J; Koury K; Gruber WC N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351 [No Abstract] [Full Text] [Related]
20. Reply to: "Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!". Rabinowich L; Shibolet O; Katchman H J Hepatol; 2022 Jan; 76(1):239-240. PubMed ID: 34634386 [No Abstract] [Full Text] [Related] [Next] [New Search]